Boston Scientific Reports Strong Q3 Growth, Acquires Nalu Medical

Boston Scientific, a leading medical device manufacturer, has reported robust third-quarter results and announced a significant acquisition, demonstrating continued growth and expansion in the medical technology sector.

Q3 Financial Performance

Boston Scientific's third-quarter revenue surpassed $5 billion, marking a 20.3% year-over-year increase. This growth, while impressive, represents a slight deceleration from the second quarter's 22% rise. The company's performance was driven by strong results across its diverse portfolio of medical devices.

Urology led the growth charge with a 28% year-over-year increase. Cardiology, Boston Scientific's largest business segment, saw a 24% climb to $2.64 billion. The medical-surgical division also performed well, rising 16% to reach $1.72 billion.

Mike Mahoney, chairman and CEO of Boston Scientific, attributed the success to the company's global team, stating, "We delivered another exceptional quarter of strong performance across businesses and regions thanks to the winning spirit of our global team."

Strategic Acquisition of Nalu Medical

In a move to bolster its pain management portfolio, Boston Scientific announced a definitive agreement to acquire the remaining equity in Nalu Medical for $533 million. Nalu Medical, a private company specializing in miniaturized neurostimulation implants for chronic pain treatment, is expected to contribute significantly to Boston Scientific's growth trajectory.

The acquisition target is forecasted to exceed $60 million in sales for 2025 and generate year-over-year growth of more than 25% in 2026. This strategic move aligns with Boston Scientific's focus on innovation and category leadership, as highlighted by Mahoney: "We are well-positioned for differentiated growth that is fueled by our category leadership strategy, relentless focus on innovation and commitment to scaling capabilities."

Future Outlook

Boston Scientific's recent performance and strategic initiatives paint a picture of a company poised for continued growth in the medical technology sector. The combination of organic growth across its existing product lines and targeted acquisitions like Nalu Medical suggests that the company is actively pursuing opportunities to expand its market presence and technological capabilities.

As the medical device industry continues to evolve, Boston Scientific's diverse portfolio and focus on innovation position it as a key player to watch in the coming quarters.